

SHORT REPORT

Open Access



Variation in KSHV prevalence between geographically proximate locations in Uganda

Angela Nalwoga^{1,2*} , Emily L. Webb³, Claudios Muserere³, Belinda Chihota³, Wendell Miley⁴, Nazzarena Labo⁴, Alison Elliott^{1,3}, Stephen Cose^{1,3}, Denise Whitby⁴ and Robert Newton⁵

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) transmission within endemic areas may vary. KSHV seroprevalence has been studied by different groups of researchers using different methods, making it difficult to make direct comparisons. Here we show results on KSHV seroprevalence using the same laboratory method from four different but geographically proximate populations in Uganda.

Blood samples from the urban Entebbe Mother and Baby Study (EMaBS), the rural General Population Cohort (GPC), the fishing community Lake Victoria Island Intervention Study on Worms and Allergy related Diseases (LaVIISWA) and the high-risk sexual behaviour Good Health for Women Project (GHWP), were tested for IgG antibody levels to K8.1 and ORF73 recombinant proteins using ELISA.

All adult participants of the EMaBS study and the GHWP were women, while the GPC (54% female) and LaVIISWA (52% female) studies had both males and females. EMaBS children were all 5 years of age while their mothers were 14 to 47 years of age. GHWP women were 15 to 45 years old, LaVIISWA participants were 1 to 72 years old while GPC participants were 1 to 103 years old. KSHV seropositivity varied in the different populations. In children aged 5 years, EMaBS had the lowest prevalence of 15% followed by GPC at 35% and LaVIISWA at 54%. In adult women, seropositivity varied from 69% (EMaBS) to 80% (LaVIISWA) to 87% (GPC) to 90% (GHWP).

The reasons for the variation in prevalence are unclear but may reflect differences in the prevalence of cofactors between these four geographically proximate populations.

Keywords: KSHV, Uganda, Seroprevalence, Various populations

Key message

We show that KSHV prevalence varies even within geographically proximate locations in Uganda. This variations could be caused by a number of co-factors including malaria, HIV and helminths infections and early age of KSHV infection. The high KSHV prevalence in various

populations may be explained by the multiple co-factors that affect KSHV acquisition and transmission.

Introduction

Uganda has amongst the highest reported incidence of Kaposi's sarcoma (KS) in the world [1] and the highest reported seroprevalence of the underlying causal agent, Kaposi's sarcoma-associated herpesvirus (KSHV) [2–4]. Unlike other human herpesviruses, KSHV varies in prevalence widely across the world [5], perhaps reflecting variation in underlying drivers of lytic replication and transmission.

* Correspondence: angelanalwoga@gmail.com

¹MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda

²Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Several risk factors for KSHV have been identified by our group, and others, including infection with HIV, malaria and helminths [2, 3, 6–11]. The distribution of these may vary between regions within the same country leading to differences in the spread of KSHV, even between geographically proximate locations.

In this manuscript, we have examined the seroprevalence of KSHV in four population cohorts in Uganda. These cohorts include an urban population (Entebbe Mother and Baby Study, EMaBS) [12], a land-locked rural population (General Population Cohort, GPC) [13, 14], a rural fishing community population in the islands of Lake Victoria (Lake Victoria Island Intervention Study on Worms and Allergy related Diseases, LaVIISWA) [15], and a high-risk sexual behaviour population recruited in an urban centre, but including highly mobile women who engage in transactional sex (Good Health for Women Project, GHWP) [16].

Methods


Data on KSHV seropositivity from the EMaBS, the GPC, LaVIISWA and the GHWP were analysed for this manuscript. The study populations are described briefly below and further details have previously been published [12, 13, 15, 16].

The Entebbe Mother and Baby Study (EMaBS; ISRCTN32849447) was a randomised double-blind, placebo-controlled trial of anthelmintic treatment during pregnancy [12, 17–19], designed to investigate the effects of helminth treatment during pregnancy on childhood responses to vaccines and infectious diseases. Pregnant mothers in their second or third trimester attending antenatal care at Entebbe general hospital were recruited between June 2003 and August 2005. A total of 2507 pregnant women from the urban Entebbe municipality and peri-urban Katabi sub-county (Fig. 1) were enrolled

in the EMaBS. Demographic and clinical details, blood and stool samples were obtained from the mothers at enrolment and 1 month after delivery, and from children at ages one, two, three, four, five, 6 and 9 years. Using plasma samples from mothers during early postpartum period and 5 years old children, we tested for KSHV antibody responses to determine KSHV seropositivity and its associated risk factors [7, 9, 10, 20]. EMaBS provided a stable urban population relative to the other populations analysed for this paper.

The General Population Cohort (GPC) is located in southwestern Uganda, in Kyamulibwa sub-county of Kalungu district [13, 21] (Fig. 1). The GPC has a population of about 22,000 people scattered across the countryside in 25 adjacent villages [22]. It is a rural community with semi-permanent structures built from locally available materials. The community is relatively stable, homogeneous and young, with 90% of residents aged less than 50 years of age. Only about 13% of the residents attained education beyond primary level [23, 24]. The GPC was established to examine the trends and determinants of the HIV epidemic in rural southwestern Uganda [25, 26]. Biennial population surveys, as well as medical surveys, are conducted at a central hub in each village among all people who have lived in the village for at least 3 months. During each medical survey, blood, biophysical and lifestyle data are collected to determine disease outcomes and risk factors for selected participants [27–29]. To determine KSHV seroprevalence in this area, we have tested plasma samples for KSHV IgG antibodies, collected at various survey rounds, the latest tested being the 24th (2014/2015) and 25th (2016) surveys [2].

The Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA) was a two-arm open cluster randomised trial (ISRCTN47196031) of



intensive versus standard antihelminthic treatment [30]. The trial was carried out in Lake Victoria island fishing villages in Koome sub-county, Mukono district, Uganda (Fig. 1), between September 2012 and August 2016. Kome islands are relatively isolated and rural, consisting of 27 villages with a relatively mobile population of approximately 16,000 people; 26 of the villages participated in the trial with the remaining village used for piloting procedures. The trial aimed to investigate the effect of helminth treatment on allergy-related outcomes in a *Schistosoma mansoni* heavily infected area. Questionnaires were administered to record household features and socio-demographic characteristics [31]. Plasma samples collected from the trial were randomly selected and tested for KSHV IgG antibodies to determine KSHV seropositivity [3].

The Good Health for Women Project (GHWP) is a high-risk sexual behaviour cohort of women who engage in transactional sex. Participants were recruited from a densely populated slum area in southern Kampala, although many were originally from rural areas and are relatively mobile, some moving frequently to find work (Fig. 1). These women work from bars, night clubs, local beer breweries, eating places, lodges and guesthouses known to provide rooms for commercial sex work. Recruitment of over 1000 women into the GHWP occurred in 2008 and three-monthly follow-up was carried out. Details of the study are shown elsewhere [32, 33]. A random sample of sera from 410 women in this cohort was selected to determine KSHV seroprevalence.

All serological analyses were done in the same laboratory at the MRC/UVRI and LSTHM Uganda Research Unit in Entebbe, Uganda. Plasma or serum samples were

tested for anti-KSHV IgG antibodies to KSHV-encoded K8.1 and latently associated nuclear antigen (LANA)/ORF73 recombinant proteins using an Enzyme-linked immunosorbent assay (ELISA). Three negative control wells and three positive control wells were included on each plate. The negative controls were used to calculate a cut-off value for each plate. The cut-off value for each plate was the average background-subtracted optical densities (OD) of the three negative control triplicates plus a constant value of 0.75 (for K8.1) or 0.35 (for ORF73/LANA). This procedure has been reported previously [34].

Statistical analysis was carried out using STATA version 13 (StataCorp, College Station, Texas USA). The survey study design of the LaVIISWA trial was not self-weighting (because the number of households selected from each village was fixed, therefore households from smaller villages were more likely to be included in the survey than households from larger villages). To allow for this non-self-weighting design and to ensure that our analyses are representative of the study area, we, therefore, took into account clustering within villages and applied village-level weights for all analyses [35, 36]. A survey weight of one and a unique cluster number were given to each participant from the other studies (EMaBS, GPC and GHWP). Logistic regression (allowing for the survey design) was used to determine associations between the study population and KSHV seropositivity.


Results

Plasma from 1164 EMaBS women and 1222 children aged 5 years, 403 women aged 15 to 45 years from GHWP, as well as males and females of all ages (7283

Table 1 Population characteristics

	EMaBS ^a n = 2386	GPC ^b n = 7283	LaVIISWA ^c n = 1571	GHWP ^d n = 403
Sample collection years	2003/2006	2014/2016	2015/2016	2008/2009
Age in years, mean (range)	24 (14, 47) ^e	23 (1, 103)	23 (1, 72)	26 (15, 45)
Age groups, years				
1–4		11% (833/7283)	14% (224/1571)	
5	51% (1222/2386)	4% (315/7283)	4% (61/1571)	
6–13		31% (2277/7283)	14% (228/1571)	
14–18	8% (196/2386)	12% (848/7283)	6% (72/1571)	2% (9/402)
19–25	25% (594/2386)	8% (601/7283)	16% (255/1571)	46% (185/402)
26–50	16% (374/2386)	21% (1527/7283)	43% (672/1571)	52% (208/402)
Above 50		12% (882/7283)	4% (59/1571)	
Sex, female	74% (1765/2386)	54% (3925/7283)	52% (770/1571)	100% (403/403)
HIV serostatus				
Children (< 13 years)	2% (22/1221)	1% (36/3126)	2% (6/283)	
Adults (14+ years)	14% (160/1164)	8% (315/3853)	21% (195/946)	38% (153/403)

HIV serostatus determine using rapid diagnostic tests ^aEMaBS-Entebbe Mother and Baby Study, ^bGPC-General Population Cohort, ^cLaVIISWA-Lake Victoria Island Intervention Study on Worms and Allergy related diseases, ^dGHWP-Good Health for Women Project, ^eOnly women from EMaBS, children were all 5 years old



(GPC) and 1571 (LaVIISWA)) were analysed (Table 1). HIV prevalence varied in the four different populations with GHWP having the highest prevalence (38%), and the GPC having the lowest (8%) among those aged 14 years and above (Table 1). Other population characteristics of the participants analysed are shown in Table 1.

First, we looked at KSHV seropositivity in the various age groups from the four different populations. KSHV seropositivity increased with increasing age, (Fig. 2). The urban Entebbe Mother and Baby Study had the lowest seropositivity in all the tested age groups while the GHWP had the highest seropositivity.

After considering the crude pattern of KSHV seropositivity, we then analysed the seropositivity of KSHV in the various study populations adjusting for age, sex and HIV serostatus. A separate statistical analysis of children aged 5 years was done because all EMaBS children included were 5 years old at the time of sampling. In these children, after accounting for the effect of sex and HIV serostatus, the odds of being KSHV seropositive were three times higher in individuals from the GPC (OR = 3.08 (2.31, 4.12), $p < 0.0001$), and seven times higher in LaVIISWA (OR = 7.81 (3.67, 16.62), $p < 0.0001$), compared to individuals from urban Entebbe (EMaBS); Table 2. This association was maintained when the age of the child was accounted for

and all children aged 1 to 13 years were included in the analysis (Table 2). The odds of being KSHV seropositive in women 14 years and over was two times, three times and four times higher in LaVIISWA (OR = 1.72 (1.22, 2.42), $p = 0.002$), GPC (OR = 2.61 (1.94, 3.52), $p < 0.0001$), and GHWP (OR = 3.90 (2.72, 5.59), $p < 0.0001$) respectively, compared to women from the EMaBS (Table 3). These differences were maintained when only women of childbearing age (14 to 49 years) were included in the analysis (Table 3). Furthermore, males over 14 years of age had similar odds of being KSHV seropositive if they were from the GPC and LaVIISWA (Table 3). GHWP and EMaBS had no males over 14 years of age.

Discussion

The worldwide incidence of KS is known to vary greatly, in large part reflecting variation in the prevalence of KSHV, the underlying cause [5]. Less is known about local variation between populations within countries, perhaps because differences between published studies may be attributed to differences between assays and approaches used, rather than reflecting real differences in prevalence. In this paper, we take advantage of results on KSHV seropositivity obtained from various Ugandan populations, tested using the same antigens and carried

Table 2 Association between KSHV seropositivity or antibody levels and study population. KSHV seropositivity in children

Study	Children 1–13 years		Children 5 years only	
	KSHV seropositivity	*OR (95% CI), <i>P</i> value	KSHV seropositivity	**OR (95% CI), <i>P</i> value
EMaBS ^a	15% (184/1222)	1	15% (184/1222)	1
GPC ^b	47% (1597/3425)	3.16 (2.38, 4.19), < 0.0001	35% (111/315)	3.08 (2.31, 4.12), < 0.0001
LaVIISWA ^c	56% (305/513)	5.79 (3.82, 8.77), < 0.0001	54% (37/61)	7.81 (3.67, 16.62), < 0.0001

*Adjusted for age group, sex and HIV serostatus ** Adjusted for sex and HIV serostatus. *OR: odds ratio. Logistic regression analysis was used for statistical analysis allowing for the survey design for the LaVIISWA trial. ^aEMaBS-Entebbe Mother and Baby Study, ^bGPC-General Population Cohort, ^cLaVIISWA-Lake Victoria Island Intervention Study on Worms and Allergy related diseases

Table 3 Association between KSHV seropositivity or antibody levels and study population. KSHV seropositivity in adults

Study	Females 14-49 years		Females 14-103 years		Males 14-103 years	
	KSHV seropositivity	*OR (95% CI), P value	KSHV seropositivity	*OR (95% CI), P value	KSHV seropositivity	*OR (95% CI), P value
EMaBS ^a	69% (806/1164)	1	69% (806/1164)	1		
GPC ^b	85% (1388/1638)	2.60 (1.92, 3.51), < 0.0001	87% (1905/2201)	2.61 (1.94, 3.52), < 0.0001	90% (1486/1657)	1
LaVIISWA ^c	79% (400/493)	1.69 (1.21, 2.36), 0.002	80% (425/519)	1.72 (1.22, 2.42), 0.002	88% (477/539)	0.71 (0.44, 1.15), 0.165
GHWP ^d	90% (361/402)	3.93 (2.74, 5.64), < 0.0001	90% (361/402)	3.9 (2.72, 5.59), < 0.0001		

* Adjusted for age group and HIV serostatus. *OR: odds ratio. Logistic regression analysis was used for statistical analysis allowing for the survey design for the LaVIISWA trial. ^aEMaBS-Entebbe Mother and Baby Study, ^bGPC-General Population Cohort, ^cLaVIISWA-Lake Victoria Island Intervention Study on Worms and Allergy related diseases, ^dGHWP-Good Health for Women Project

out by the same group of people from the same laboratory. Additionally, the glycoprotein K8.1 and the latent protein latently associated nuclear antigen (LANA)/ORF73 were used as antigens in the ELISA. These when used in combination have been shown to be very specific and sensitive at detecting HHV8 specific antibodies [34, 37, 38]. In summary, we find that prevalence varies significantly between cohorts recruited from geographically proximate locations.

Here we show that a relatively stable urban population (EMaBS) has the lowest KSHV prevalence compared to the other populations. This may be attributed to the lower occurrence of putative risk factors for KSHV lytic replication and transmission, such as, malaria and helminthic parasites.

The GHWP population was included in the analysis because of its uniqueness in comparison to the other populations. It is an urban population with a high HIV risk. It is a very mobile, high-risk sexual behaviour cohort with an HIV seroprevalence of 38%. These women had the highest risk of being KSHV seropositive. This KSHV risk is probably attributable to HIV and behavioural practices, involving salivary exchange. Additionally, many of the women are also highly mobile, moving frequently between the urban setting and more rural areas for work hence increasing their risk of acquiring infections such as KSHV.

After GHWP, the Lake Victoria Island people and the rural GPC people had higher KSHV seroprevalence compared to EMaBS. The highly mobile Island communities of Lake Victoria have high HIV incidence, schistosomiasis, other infectious diseases [3]. We have previously shown an association between schistosomiasis infection and KSHV seropositivity and antibody levels in these communities [3]. These factors may explain the high risk of KSHV infection in this cohort. The rural GPC is a relatively stable population but has a high KSHV seropositivity probably due to factors such as frequent malaria infections (many asymptomatic), which could modulate the immune system impacting on KSHV viral control and transmission.

In conclusion, KSHV prevalence varies even within geographically proximate locations in Uganda. This variations could be caused by a number of co-factors including malaria, HIV and helminths infections and early age of KSHV infection. The high KSHV prevalence in various populations may be explained by the multiple co-factors that affect KSHV acquisition and transmission.

Acknowledgements

Blood samples analysed and demographic data shown in this manuscript were collected by the EMaBS, GPC, GHWP and LaVIISWA studies teams.

Authors' contributions

All authors contributed significantly to the manuscript. The author(s) read and approved the final manuscript.

Funding

This research has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract Number. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute. It also received support from the Department of Immunology and Microbiology University of Colorado Anschutz medical campus NIH grant number: 1 RO1 CA239588-01. It received funding from the African Partnership for Chronic Disease Research (APCDR), University of Cambridge, United Kingdom. It also received support from the Makerere University/UVRI Centre of Excellence for Infection and Immunity Research and Training (MUII-plus). MUII-plus is supported through the DELTAS Africa Initiative (Grant no. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no.107743) and the UK Government. The MRC/UVRI and LSHTM Uganda Research Unit is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 Programme supported by the European Union. The EMaBS and LaVIISWA trial were funded by the Wellcome Trust, UK, grant numbers 064693, 079110 and 095778 to AME.

Availability of data and materials

Data can be made available on request.

Ethics approval

Ethical approval was provided by the Uganda Virus Research Institute-Research and Ethics Committee (UVRI-REC), the Uganda National Council for Science and Technology (UNCST) and the London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee. Participants (or their parents or guardians in case of children below 18 years) provided written informed

consent for participation in the studies and storage of their samples for future use. Also, written informed assent was given by participants aged 8 to 17 years.

Consent for publication

All authors consented the manuscript for publication.

Competing interests

Non declared.

Author details

¹MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda. ²Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. ³London School of Hygiene & Tropical Medicine, London, UK. ⁴Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. ⁵University of York, York, UK.

Received: 16 May 2020 Accepted: 15 July 2020

Published online: 23 July 2020

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424.
- Nalwoga A, Cose S, Nash S, Miley W, Asiki G, Kusemererwa S, Yarchoan R, et al. Relationship between Anemia, malaria Coinfection, and Kaposi sarcoma-associated Herpesvirus Seropositivity in a population-based study in rural Uganda. *J Infect Dis*. 2018;218(7):1061–5.
- Nalwoga A, Webb EL, Chihota B, Miley W, Walusimbi B, Nassuuna J, Sanya RE, et al. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. *PLoS Negl Trop Dis*. 2019;13(10):e0007776.
- Newton R, Labo N, Wakeham K, Miley W, Asiki G, Johnston WT, Whitby D. Kaposi sarcoma-associated Herpesvirus in a rural Ugandan cohort, 1992–2008. *J Infect Dis*. 2018;217(2):263–9.
- Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. *Nat Rev Dis Primers*. 2019;5(1):9.
- Nalwoga A, Cose S, Wakeham K, Miley W, Ndiabaza J, Drakeley C, Elliott A, et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. *Tropical Med International Health: TM & IH*. 2015;20(5):665–72.
- Nalwoga A, Miley W, Labo N, Elliott A, Cose S, Whitby D, Newton R. Age of infection with Kaposi sarcoma-associated Herpesvirus and subsequent antibody values among children in Uganda. *Pediatr Infect Dis J*. 2018;37(8):e225–e8.
- Nalwoga A, Nakibuule M, Marshall V, Miley W, Labo N, Cose S, Whitby D, et al. Risk factors for Kaposi's sarcoma associated herpesvirus (KSHV) DNA in blood and in saliva in rural Uganda. *Clin Infectious Diseases*. 2019. <https://doi.org/10.1093/cid/ciz916>. PubMed PMID: 31555829.
- Wakeham K, Webb EL, Sebina I, Muhangi L, Miley W, Johnson WT, Ndiabaza J, et al. Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. *Infectious Agents Cancer*. 2011;6(1):15.
- Wakeham K, Webb EL, Sebina I, Nalwoga A, Muhangi L, Miley W, Johnston WT, et al. Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. *J Acquir Immune Defic Syndr*. 2013; 63(2):228–33.
- Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, Hines-Boykin R, Goedert JJ, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. *Int J Cancer*. 2007; 120(2):321–8.
- Webb EL, Mawa PA, Ndiabaza J, Kizito D, Namatovu A, Kyosiimire-Lugemwa J, Nanteza B, et al. Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011;377(9759):52–62.
- Asiki G, Murphy G, Nakiyingi-Miiri J, Seeley J, Nsubuga RN, Karabarinde A, Waswa L, et al. The general population cohort in rural South-Western Uganda: a platform for communicable and non-communicable disease studies. *Int J Epidemiol*. 2013;42(1):129–41.
- Asiki G, Reniers G, Newton R, Baisley K, Nakiyingi-Miiri J, Slaymaker E, Kasamba I, et al. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991–2012). *Aids*. 2016;30(3):487–93.
- Sanya RE, Nkurunungi G, Hoek Spaans R, Nampijja M, O'Hara G, Kizindo R, Oduru G, et al. The impact of intensive versus standard anthelmintic treatment on allergy-related outcomes, Helminth infection intensity, and Helminth-related morbidity in Lake Victoria fishing communities, Uganda: results from the LaVISA cluster-randomized trial. *Clin Infect Dis*. 2019; 68(10):1665–74.
- Kamacocko O, Mayanja Y, Bagiere D, Namale G, Hansen CH, Seeley J. Predictors of lost to follow-up in a "test and treat" programme among adult women with high-risk sexual behavior in Kampala, Uganda. *BMC Public Health*. 2020;20(1):353.
- Elliott AM, Namujju PB, Mawa PA, Quigley MA, Nampijja M, Nkurunziza PM, Belisle JT, et al. A randomised controlled trial of the effects of albendazole in pregnancy on maternal responses to mycobacterial antigens and infant responses to Bacille Calmette-Guerin (BCG) immunisation [ISRCTN32849447]. *BMC Infect Dis*. 2005;5:115.
- Elliott AM, Ndiabaza J, Mpairwe H, Muhangi L, Webb EL, Kizito D, Mawa P, et al. Treatment with anthelmintics during pregnancy: what gains and what risks for the mother and child? *Parasitology*. 2011;138(12):1499–507.
- Webb EL, Nampijja M, Kaweesa J, Kizindo R, Namutebi M, Nakazibwe E, Oduru G, et al. Helminths are positively associated with atopy and wheeze in Ugandan fishing communities: results from a cross-sectional survey. *Allergy*. 2016;71(8):1156–69.
- Wakeham K, Johnston WT, Nalwoga A, Webb EL, Mayanja BN, Miley W, Elliott AM, et al. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. *Int J Cancer*. 2015;136(12):2822–30.
- Kaleebu P, Kamali A, Seeley J, Elliott AM, Katongole-Mbidde E. The Medical Research Council (UK)/Uganda virus research institute Uganda research unit on AIDS--25 years of research through partnerships'. *Tropical Med Int Health: TM & IH*. 2015;20(2):E1–10.
- Asiki G, Baisley K, Kamali A, Kaleebu P, Seeley J, Newton R. A prospective study of trends in consumption of cigarettes and alcohol among adults in a rural Ugandan population cohort, 1994–2011. *Tropical Med Int Health: TM & IH*. 2015;20(4):527–36.
- Asiki G, Baisley K, Newton R, Marions L, Seeley J, Kamali A, Smedman L. Adverse pregnancy outcomes in rural Uganda (1996–2013): trends and associated factors from serial cross sectional surveys. *BMC Pregnancy Childbirth*. 2015;15:279.
- Kamali A, Nsubuga RN, Ruzagira E, Bahemuka U, Asiki G, Price MA, Newton R, et al. Heterogeneity of HIV incidence: a comparative analysis between fishing communities and in a neighbouring rural general population, Uganda, and implications for HIV control. *Sex Transm Infect*. 2016;92(6):447–54.
- Kamali A, Carpenter LM, Whitworth JA, Pool R, Ruberantwari A, Ojwiya A. Seven-year trends in HIV-1 infection rates, and changes in sexual behaviour, among adults in rural Uganda. *Aids*. 2000;14(4):427–34.
- Kinyanda E, Waswa L, Baisley K, Maher D. Prevalence of severe mental distress and its correlates in a population-based study in rural south-West Uganda. *BMC Psychiatry*. 2011;11:97.
- Kengeya-Kayondo JF, Kamali A, Nunn AJ, Ruberantwari A, Wagner HU, Mulder DW. Incidence of HIV-1 infection in adults and socio-demographic characteristics of seroconverters in a rural population in Uganda: 1990–1994. *Int J Epidemiol*. 1996;25(5):1077–82.
- Murphy GA, Asiki G, Ekoru K, Nsubuga RN, Nakiyingi-Miiri J, Young EH, Seeley J, et al. Sociodemographic distribution of non-communicable disease risk factors in rural Uganda: a cross-sectional study. *Int J Epidemiol*. 2013; 42(6):1740–53.
- Shafer LA, Biraro S, Nakiyingi-Miiri J, Kamali A, Ssematimba D, Ouma J, Ojwiya A, et al. HIV prevalence and incidence are no longer falling in Southwest Uganda: evidence from a rural population cohort 1989–2005. *Aids*. 2008;22(13):1641–9.
- Nampijja M, Webb EL, Kaweesa J, Kizindo R, Namutebi M, Nakazibwe E, Oduru G, et al. The Lake Victoria Island intervention study on Worms and allergy-related diseases (LaVISA): study protocol for a randomised controlled trial. *Trials*. 2015;16:187.
- Sanya RE, Nkurunungi G, Hoek Spaans R, Nampijja M, O'Hara G, Kizindo R, Oduru G, et al. The impact of intensive versus standard anthelmintic treatment on allergy-related outcomes, helminth infection intensity and

- helminth-related morbidity in Lake Victoria fishing communities, Uganda: results from the LaVIISWA cluster randomised trial. *Clin Infectious Diseases*. 2018;68(10):1665-74. <https://doi.org/10.1093/cid/ciy761>. PubMed PMID: 30202872; PMCID: PMC6495012.
32. Bukenya J, Vandepitte J, Kwikiriza M, Weiss HA, Hayes R, Grosskurth H. Condom use among female sex workers in Uganda. *AIDS Care*. 2013;25(6):767-74.
 33. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, Hughes P, Hayes R, et al. HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. *Sex Transm Dis*. 2011;38(4):316-23.
 34. Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, Busch MP, et al. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. *J Immunol Methods*. 2010;356(1-2):39-46.
 35. Hayes R, Moulton L. Cluster randomised trials. Boca Ranton: Taylor & Francis CrossRef Google Scholar; 2009.
 36. Hayes RJ, Moulton LH. Cluster randomised trials: CRC press; 2017.
 37. Braz-Silva PH, Tozetto-Mendoza TR, Sumita LM, Freire W, Palmieri M, do Canto AM, Avelino-Silva VI, et al. Prospective study of human herpesvirus 8 oral shedding, viremia, and serological status among human immunodeficiency virus seropositive and seronegative individuals in Sao Paulo, Brazil. *J Oral Microbiol*. 2017;9(1):1384287.
 38. Schatz O, Monini P, Bugarini R, Neipel F, Schulz TF, Andreoni M, Erb P, et al. Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. *J Med Virol*. 2001;65(1):123-32.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

